Back to Trials
NCT07498010PHASE2Recruiting

Doxycycline Use in Post-Operative Seromas

University of Miami

Start Date

5/31/2026

Completion Date

10/1/2027

Summary

Seromas are collections of serous fluid that can develop following surgical procedures and may persist as fibrous-lined pseudocysts if not adequately treated. In orthopedic surgery, particularly after arthroplasty, seromas can impair wound healing, increase pain, and limit postoperative rehabilitation, potentially compromising patient recovery. Current treatment strategies including compression, percutaneous aspiration, and repeat surgical intervention have variable success, and aspiration carries the risk of introducing bacteria into an otherwise sterile fluid collection. Sclerotherapy has been proposed as an alternative strategy to induce fibrosis within the cavity and eliminate the potential space. Doxycycline, a tetracycline antibiotic commonly used for pleurodesis, has demonstrated sclerosing properties through mechanisms including mesothelial cell destruction, inhibition of fibrinolysis, and stimulation of fibroblast activity. While doxycycline sclerotherapy has shown success in treating conditions such as Morel-Lavallée lesions and has been described in isolated orthopedic case reports, its role in managing postoperative seromas after arthroplasty remains poorly studied. Further investigation is needed to determine whether doxycycline injection may serve as a safe and effective treatment to reduce persistent seromas and the need for additional interventions in orthopedic patients.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Patient with seroma formation following orthopedic procedure * \>18 years old * Willing and able to provide informed consent * Pre-operative imaging (US, CT) demonstrating seroma formation Exclusion Criteria: * Pregnancy or lactation * Age \<18 years * Known allergy to tetracyclines * Significant hepatic or renal dysfunction (Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) \>3× Upper Limit of Normal (ULN), Creatinine Clearance (CrCl \<30 mL/min) * History of photosensitivity or photodermatosis * Concurrent isotretinoin or retinoid therapy * Current use of anticoagulants or immunosuppressants * Active GI ulceration or esophageal disease * Any condition likely to impair adherence or drug absorption (e.g., malabsorption syndromes)

Interventions

DRUG

Doxycycline

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Seroma

Locations

University of Miami

Coral Gables, Florida 33146

United States